NASDAQ:SYBXSynlogic Stock Price, Forecast & News

Synlogic's stock was trading at $1.54 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, SYBX stock has increased by 37.0% and is now trading at $2.11. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Synlogic in the last year. There are currently 1 sell rating, 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Synlogic.

Synlogic is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Synlogic.

Synlogic Inc (NASDAQ:SYBX) posted its quarterly earnings results on Friday, May, 8th. The biotechnology company reported ($0.46) EPS for the quarter, missing the Zacks' consensus estimate of ($0.43) by $0.03. The biotechnology company had revenue of $0.10 million for the quarter, compared to analysts' expectations of $0.73 million. Synlogic had a negative return on equity of 33.46% and a negative net margin of 2,733.25%. View Synlogic's earnings history.

Shares of Synlogic reverse split on Monday, August 28th 2017. The 1-7 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 25th 2017. An investor that had 100 shares of Synlogic stock prior to the reverse split would have 14 shares after the split.

6 equities research analysts have issued 1-year price objectives for Synlogic's shares. Their forecasts range from $2.00 to $25.00. On average, they expect Synlogic's stock price to reach $13.40 in the next twelve months. This suggests a possible upside of 535.1% from the stock's current price. View analysts' price targets for Synlogic.

News stories about SYBX stock have trended negative on Friday, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Synlogic earned a news sentiment score of -2.3 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news about Synlogic.

Synlogic saw a decline in short interest in the month of June. As of June 30th, there was short interest totaling 502,900 shares, a decline of 25.5% from the June 15th total of 674,700 shares. Based on an average trading volume of 288,700 shares, the short-interest ratio is presently 1.7 days. Approximately 2.7% of the shares of the stock are sold short. View Synlogic's Current Options Chain.

Some companies that are related to Synlogic include Bicycle Therapeutics (BCYC), OrganiGram (OGI), ProQR Therapeutics (PRQR), AMAG Pharmaceuticals (AMAG), Northwest Biotherapeutics (NWBO), TAIWAN LIPOSOME/S (TLC), Lannett (LCI), IVERIC bio (ISEE), MediciNova (MNOV), Verrica Pharmaceuticals (VRCA), Verastem (VSTM), REDHILL BIOPHAR/S (RDHL), CymaBay Therapeutics (CBAY), Selecta Biosciences (SELB) and Agile Therapeutics (AGRX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Synlogic investors own include Reata Pharmaceuticals (RETA), Approach Resources (AREX), Precision Drilling (PDS), First Financial Bankshares (FFIN), Corbus Pharmaceuticals (CRBP), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), SCYNEXIS (SCYX) and Verastem (VSTM).

Synlogic trades on the NASDAQ under the ticker symbol "SYBX."

Shares of SYBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of SYBX stock can currently be purchased for approximately $2.11.

Synlogic has a market capitalization of $69.29 million and generates $2.22 million in revenue each year. The biotechnology company earns $-51,370,000.00 in net income (profit) each year or ($1.70) on an earnings per share basis. Synlogic employs 74 workers across the globe.

The official website for Synlogic is www.synlogictx.com.

Synlogic's mailing address is 301 Binney St. Suite 402, Cambridge MA, 02142. The biotechnology company can be reached via phone at 617-401-9975 or via email at [email protected]